Shares of Bionano Genomics (BNGO) experienced a steep decline of 7.46% during midday trading on Monday, September 10, 2024. The sharp sell-off can be attributed to two significant events impacting the company.
Firstly, BTIG analyst Mark Massaro downgraded the stock from a "Buy" rating to a "Neutral" rating. In his research note, Massaro expressed concerns about the company's ability to achieve widespread adoption of its optical genome mapping technology, citing competition from other technologies and limited resources as potential obstacles to growth.
Additionally, Bionano Genomics announced plans to lay off approximately 45% of its workforce, amounting to 84 employees, including the Chief Financial Officer, Gulsen Kama. This move is part of a broader cost-cutting plan aimed at saving between $25 million and $30 million in annual operating expenses by the fourth quarter.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。